

## Part VI: Summary of the risk management plan

### Summary of risk management plan for

#### **"Trabectedin SUN 0.25 mg powder for concentrate for solution for infusion and**

#### **Trabectedin SUN 1 mg powder for concentrate for solution for infusion"**

(trabectedin)

This is a summary of the risk management plan (RMP) for "Trabectedin SUN 0.25 mg powder for concentrate for solution for infusion and Trabectedin SUN 1 mg powder for concentrate for solution for infusion". The RMP details important risks of "Trabectedin SUN 0.25 mg powder for concentrate for solution for infusion and Trabectedin SUN 1 mg powder for concentrate for solution for infusion", how these risks can be minimised and how more information will be obtained about "Trabectedin SUN 0.25 mg powder for concentrate for solution for infusion and Trabectedin SUN 1 mg powder for concentrate for solution for infusion" 'risks and uncertainties (missing information).

"Trabectedin SUN 0.25 mg powder for concentrate for solution for infusion and Trabectedin SUN 1 mg powder for concentrate for solution for infusion" summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how "Trabectedin SUN 0.25 mg powder for concentrate for solution for infusion and Trabectedin SUN 1 mg powder for concentrate for solution for infusion" should be used.

This summary of the RMP for "Trabectedin SUN 0.25 mg powder for concentrate for solution for infusion and Trabectedin SUN 1 mg powder for concentrate for solution for infusion" should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of Trabectedin SUN 0.25 mg powder for concentrate for solution for infusion and Trabectedin SUN 1 mg powder for concentrate for solution for infusion's RMP.

### **I. The medicine and what it is used for**

"Trabectedin SUN 0.25 mg powder for concentrate for solution for infusion and Trabectedin SUN 1 mg powder for concentrate for solution for infusion" is indicated for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Trabectedin in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer (see SmPC for the full indication) and it is given as an intravenous infusion over 24 hours with a three-week interval between cycles.

### **II. Risks associated with the medicine and activities to minimise or further characterise the risks**

Important risks of "Trabectedin SUN 0.25 mg powder for concentrate for solution for infusion and Trabectedin SUN 1 mg powder for concentrate for solution for infusion", together with measures to minimise such risks and the proposed studies for learning more about "Trabectedin SUN 0.25 mg powder for concentrate for solution for infusion and Trabectedin SUN 1 mg powder for concentrate for solution for infusion" 's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute **routine risk minimisation measures**.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of "Trabectedin SUN 0.25 mg powder for concentrate for solution for infusion and Trabectedin SUN 1 mg powder for concentrate for solution for infusion" is not yet available, it is listed under 'missing information' below.

## **II.A List of important risks and missing information**

Important risks of "Trabectedin SUN 0.25 mg powder for concentrate for solution for infusion and Trabectedin SUN 1 mg powder for concentrate for solution for infusion" are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered.

Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of "Trabectedin SUN 0.25 mg powder for concentrate for solution for infusion and Trabectedin SUN 1 mg powder for concentrate for solution for infusion".

Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

<b>List of important risks and missing information</b>	
<b>Important identified risks</b>	<b>Injection site reactions</b>
<b>Important potential risks</b>	<b>Acute Myeloid Leukaemia/ Myelodysplasia (AML/ MDS) Cardiac Dysfunction Pancreatitis, Lipase and/or Amylase increased</b>
<b>Missing information</b>	<b>None</b>

## **II.B Summary of important risks**

The safety information in the proposed Product Information is aligned to the reference medicinal product Yondelis<sup>1, 2</sup>, MAH: Pharma Mar S.A/ Immedica.

## **II.C Post-authorisation development plan**

### **II.C.1 Studies which are conditions of the marketing authorisation**

There are no studies which are conditions of the marketing authorisation or specific obligation of "Trabectedin SUN 0.25 mg powder for concentrate for solution for infusion and Trabectedin SUN 1 mg powder for concentrate for solution for infusion".

### **II.C.2 Other studies in post-authorisation development plan**

There are no studies required for "Trabectedin SUN 0.25 mg powder for concentrate for solution for infusion and Trabectedin SUN 1 mg powder for concentrate for solution for infusion".